FindTrial
Sign In

ONCOVIN 1 mg

DRUG3 trials

Sponsors

French Innovative Leukemia Organization, LYSARC, Institut Curie

Conditions

Diffuse Large B-Cell LymphomaPatients with previously untreated Richter’s syndrome (RS)Retinoblastomadefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology.

Phase 2

FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
RecruitingCTIS2022-501554-11-00
French Innovative Leukemia Organizationdefined as the transformation of chronic lymphocytic leukemia (CLL) into high-grade lymphoma of diffuse large B-cell lymphoma (DLBCL) histology., Patients with previously untreated Richter’s syndrome (RS)
Start: 2024-03-21Target: 40Updated: 2025-12-24
VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or older
Active, not recruitingCTIS2023-507286-25-00
LYSARCDiffuse Large B-Cell Lymphoma
Start: 2021-12-23Target: 45Updated: 2025-12-30
RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated
Active, not recruitingCTIS2024-514844-10-00
Institut CurieRetinoblastoma
Start: 2010-03-18Target: 195Updated: 2025-07-01